Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human HMGN1 ELISA Kit (AC2421)
Cat.#: ASET-1010
Specifications
Description Human HMGN1 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human HMGN1 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 5.13 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 75-1200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-2308 Human Gli1 ELISA Kit (AC3719) Quantitative inquiry ASET-2012 Human GIRK2 ELISA Kit (AC3423) Quantitative inquiry ASET-1563 Rat VIP ELISA Kit (AC2974) Quantitative inquiry ASET-2424 Human Noelin ELISA Kit (AC3835) Quantitative inquiry ASET-1921 Mouse Semaphorin 3c ELISA Kit (AC3332) Quantitative inquiry ASET-2182 Human Midkine ELISA Kit (AC3593) Quantitative inquiry ASET-1881 Human GJB2 ELISA Kit (AC3292) Quantitative inquiry ASET-1704 Human Tyrosine Hydroxylase ELISA Kit (AC3115) Quantitative inquiry ASET-2067 Rat GMFB ELISA Kit (AC3478) Quantitative inquiry ASET-2431 Estradiol ELISA Kit (AC3842) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket